DOCSLIB.ORG

Supplementary Information.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Information.Pdf Supplementary Information Whole transcriptome profiling reveals major cell types in the cellular immune response against acute and chronic active Epstein‐Barr virus infection Huaqing Zhong1, Xinran Hu2, Andrew B. Janowski2, Gregory A. Storch2, Liyun Su1, Lingfeng Cao1, Jinsheng Yu3, and Jin Xu1 Department of Clinical Laboratory1, Children's Hospital of Fudan University, Minhang District, Shanghai 201102, China; Departments of Pediatrics2 and Genetics3, Washington University School of Medicine, Saint Louis, Missouri 63110, United States. Supplementary information includes the following: 1. Supplementary Figure S1: Fold‐change and correlation data for hyperactive and hypoactive genes. 2. Supplementary Table S1: Clinical data and EBV lab results for 110 study subjects. 3. Supplementary Table S2: Differentially expressed genes between AIM vs. Healthy controls. 4. Supplementary Table S3: Differentially expressed genes between CAEBV vs. Healthy controls. 5. Supplementary Table S4: Fold‐change data for 303 immune mediators. 6. Supplementary Table S5: Primers used in qPCR assays. Supplementary Figure S1. Fold‐change (a) and Pearson correlation data (b) for 10 cell markers and 61 hypoactive and hyperactive genes identified in subjects with acute EBV infection (AIM) in the primary cohort. Note: 23 up‐regulated hyperactive genes were highly correlated positively with cytotoxic T cell (Tc) marker CD8A and NK cell marker CD94 (KLRD1), and 38 down‐regulated hypoactive genes were highly correlated positively with B cell, conventional dendritic cell (cDC), Treg and granulocyte markers. Supplementary Table S1 -Clinical data and EBV lab results EBV DNA load in EBV DNA load in Time at Days HTA2.0 qPCR Flow cytometry EBV VCA- EBV VCA- Patient ID Gender Age Group Cohort plasma (copies/ml white blood cells EBV-NA sampling from Symtoms hospitolized Days to recovery (outcome) microarray assay assay IgM IgG blood) (copies/ml blood) disease onset (total) 15VC1799 M 27 m AIM Primary Yes Yes 1.34E+04 n/a (+) (+) (-) 5 d fever, tonsil swelling, cervical lymphadenopathy 3 14 15VC1803 F 18 m AIM Primary Yes Yes undetectable 3.58E+03 (+) (+) (-) 3 d fever, cough, tonsil swelling, cervical lymphadenopathy 3 15 15VC2293 M 4 y AIM Primary Yes Yes undetectable 2.38E+03 (+) (+) (-) 2 d fever, cough, tonsil swelling, cervical lymphadenopathy, liver enlargement 3 15 fever, sore throat, tonsil swelling, cervical lymphadenopathy, liver 15VC2386 F 3 y AIM Primary Yes Yes 1.03E+04 n/a (+) (+) (-) 2 d 820 enlargement ED483 M 24 m AIM Primary Yes Yes undetectable 1.07E+05 (+) (+) (-) 2 d fever, tonsil swelling, enlargement of liver & spleen 3 15 fever, sore throat, tonsil swelling, cervical lymphadenopathy, enlargement ED490 M 12 m AIM Primary Yes Yes 3.68E+03 5.13E+05 (+) (+) (-) 7 d 520 of liver & spleen fever, jaundice, tonsil swelling, cervical lymphadenopathy, enlargement of 15VC2295 F 3 y CAEBV Primary Yes Yes 5.46E+05 n/a (-) (+) (+) 2 m 45 hemophagocytic syndrome liver & spleen, ALT & AST elevated fever, cervical lymphadenopathy, enlargement of liver & spleen, ALT & disease continued, with recurrence 15VC2407 M 9 y CAEBV Primary Yes Yes 1.46E+07 n/a (-) (+) (+) 3 m 17 AST elevated of 2 times disease continued, with recurrence 15VC2414 M 15 y CAEBV Primary Yes Yes 3.44E+03 n/a (-) (+) (+) 12 m fever, tonsil swelling, splenectomy 79 of 2 times disease continued, with recurrence 15VC2656 F 2 y CAEBV Primary Yes Yes 7.70E+03 n/a (-) (+) (+) 3 m fever, enlargement of liver & spleen, ALT & AST elevated 13 of 2 times disease continued, with recurrence 15VC3454 M 12 y CAEBV Primary Yes Yes 3.60E+05 n/a (-) (+) (+) 14 m fever, skin impetigo, cervical lymphadenopathy, liver enlargement 27 of 3 times C13 M 1 y CTRL Primary Yes Yes undetectable n/a (-) (+) (-) C15 F 3 y CTRL Primary Yes Yes undetectable n/a (-) (+) (+) C21 F 1 y CTRL Primary Yes Yes undetectable n/a (-) (+) (-) C22 M 3 y CTRL Primary Yes Yes undetectable n/a (-) (+) (+) C23 M 3 y CTRL Primary Yes Yes undetectable n/a (-) (+) (+) C24 F 4 y CTRL Primary Yes Yes undetectable n/a (-) (+) (+) fever, palpebral edema, sore throat, skin rash, tonsil swelling, cervical 16VC0100 F 4 y AIM Secondary Yes 1.80E+03 1.55E+06 (+) (+) (-) 6 d outpatient 23 lymphadenopathy fever, sore throat, tonsil swelling, cervical lymphadenopathy, ALT & AST 16VC9468 F 9 y AIM Secondary Yes 6.17E+03 n/a (+) (+) (-) 7 d 427 elevated 16VC9539 F 3 y AIM Secondary Yes undetectable 2.01E+06 (+) (+) (-) 3 d fever, palpebral edema, tonsil swelling, cervical lymphadenopathy outpatient 29 fever, sore throat, skin rash, palpebral edema, tonsil swelling, cervical 16VC9546 M 1 y AIM Secondary Yes 3.98E+03 n/a (+) (+) (-) 4 d outpatient 24 lymphadenopathy, enlargement of liver & spleen, ALT & AST elevated 16VC9677 F 2 y AIM Secondary Yes undetectable 1.46E+05 (+) (-) (-) 4 d fever, sore throat, tonsil swelling, cervical lymphadenopathy outpatient 22 16VC9724 F 1 y AIM Secondary Yes undetectable 1.63E+04 (+) (+) (-) 3 d fever, sore throat, skin rash, tonsil swelling, cervical lymphadenopathy, outpatient 19 16VC9731 M 2 y AIM Secondary Yes 2.88E+03 3.76E+06 (+) (+) (-) 4 d fever, sore throat, cough, tonsil swelling outpatient 19 fever, palpebral edema, tonsil swelling, cervical lymphadenopathy, 16VC9784 M 4 y AIM Secondary Yes undetectable 5.51E+04 (+) (+) (-) 4 d 323 enlargement of liver & spleen, ALT & AST elevated 16VC9799 M 12 y AIM Secondary Yes undetectable 2.80E+04 (+) (+) (-) 10 d fever, cough, sore throat, tonsil swelling, cervical lymphadenopathy outpatient 30 fever, palpebral edema, sore throat, tonsil swelling, cervical 16VC9842 M 3 y AIM Secondary Yes 1.02E+03 2.30E+05 (+) (+) (-) 3 d 313 lymphadenopathy fever, cough, tonsil swelling, cervical lymphadenopathy, enlargement of ED482 * F 5 y AIM Secondary Yes undetectable 1.07E+04 (+) (+) (-) 10 d 923 liver & spleen fever, palpebral edema, tonsil swelling, cervical lymphadenopathy, ALT & ED504 * F 12 y AIM Secondary Yes undetectable 2.17E+04 (+) (+) (-) 3 d 519 AST elevated IM-1(17ES171) M 3 y AIM Secondary cell surface 1.26E+03 3.53E+04 (+) (+) (-) 7 d fever, tonsil swelling, cervical lymphadenopathy, ALT & AST elevated outpatient 20 IM-10(17ES204) F 1 y AIM Secondary cell surface undetectable 1.87E+03 (+) (+) (-) 3 d fever, tonsil swelling, cervical lymphadenopathy, ALT & AST elevated 5 26 fever, cough, tonsil swelling, cervical lymphadenopathy, ALT & AST IM-11(17ES2247) M 9 y AIM Secondary intracellular undetectable 5.91E+03 (+) (+) (-) 4 d outpatient 23 elevated IM-12(17ES2279) M 3 y AIM Secondary intracellular 1.57E+03 3.01E+04 (+) (+) (-) 4 d fever, palpebral edema, tonsil swelling, cervical lymphadenopathy, outpatient 25 fever, palpebral edema, tonsil swelling, sore throat, cervical IM-13(17ES2281) M 7 y AIM Secondary intracellular 7.24E+03 3.40E+05 (+) (+) (-) 2 d 318 lymphadenopathy, fever, palpebral edema, tonsil swelling, cervical lymphadenopathy, IM-14(17ES3780) M 2 y AIM Secondary intracellular 2.39E+03 4.50E+05 (+) (+) (-) 3 d 317 palpebral edema fever, sore throat, cough, tonsil swelling, cervical lymphadenopathy, ALT & IM-15(17ES3929) F 3 y AIM Secondary intracellular 6.06E+03 1.60E+06 (+) (+) (-) 2 d outpatient 23 AST elevated IM-16(17ES3979) M 2 y AIM Secondary intracellular undetectable 1.30E+05 (+) (+) (-) 4 d fever, sore throat, tonsil swelling, cervical lymphadenopathy outpatient 24 IM-17(17ES3998) M 2 y AIM Secondary intracellular undetectable 3.64E+04 (+) (+) (-) 3 d fever, sore throat, tonsil swelling, cervical lymphadenopathy 3 27 fever, palpebral edema, cough, tonsil swelling, cervical lymphadenopathy, IM-18(17ES4051) M 3 y AIM Secondary intracellular undetectable 9.29E+03 (+) (+) (-) 4 d 422 enlargement of liver & spleen, ALT & AST elevated IM-2(17ES182) M 2 y AIM Secondary cell surface undetectable undetectable (+) (-) (-) 2 d fever, skin rash, cough, cervical lymphadenopathy 310 fever, palpebral edema, tonsil swelling, cervical lymphadenopathy, ALT & IM-3(17ES183) M 7 y AIM Secondary cell surface undetectable 3.39E+03 (+) (+) (-) 2 d 322 AST elevated IM-4(17ES310) M 10 y AIM Secondary cell surface undetectable 3.20E+04 (+) (+) (-) 3 d fever, palpebral edema, tonsil swelling, cervical lymphadenopathy 7 18 IM-5(17ES322) M 4 y AIM Secondary cell surface undetectable 1.20E+03 (+) (+) (-) 5 d fever, cough, tonsil swelling 6 34 IM-6(17ES509) M 2 y AIM Secondary cell surface undetectable 4.21E+05 (+) (-) (-) 6 d fever, cough, tonsil swelling outpatient 24 IM-7(17ES618) M 7 y AIM Secondary cell surface undetectable 1.19E+03 (+) (-) (-) 3 d fever, tonsil swelling, cervical lymphadenopathy, ALT & AST elevated 3 16 IM-8(17ES619) M 4 y AIM Secondary cell surface undetectable 2.01E+03 (+) (+) (-) 4 d fever, sore throat, cough 3 26 IM-9(17ES1904) M 1 y AIM Secondary cell surface 1.54E+04 9.62E+05 (+) (-) (-) 3 d fever, tonsil swelling, cervical lymphadenopathy 3 14 IM41 F 5Y AIM Secondary population undetectable 2.40E+03 (+) (-) (-) 3d fever, cough, tonsil swelling outpatient 10 IM42 F 2Y AIM Secondary population undetectable 1.65E+05 (+) (+) (-) 4 d fever, tonsil swelling, cervical lymphadenopathy，palpebral edema outpatient 15 IM43 M 2Y AIM Secondary population 4.70E+03 2.00E+05 (+) (+) (-) 5d fever, tonsil swelling, cervical lymphadenopathy，palpebral edema 3 18 Page 1 of 2 EBV DNA load in EBV DNA load in Time at Days HTA2.0 qPCR Flow cytometry EBV VCA- EBV VCA- Patient ID Gender Age Group Cohort plasma (copies/ml white blood cells EBV-NA sampling from Symtoms hospitolized Days to recovery (outcome) microarray assay assay IgM IgG blood) (copies/ml blood) disease onset
Load more

Recommended publications
  • Case Report a Fetus with Kabuki Syndrome 2 Detected by Chromosomal Microarray Analysis
    Int J Clin Exp Pathol 2020;13(2):302-306 www.ijcep.com /ISSN:1936-2625/IJCEP0104334 Case Report A fetus with Kabuki syndrome 2 detected by chromosomal microarray analysis Chen-Zhao Lin1, Bi-Ru Qi1, Jian-Su Hu2, Xiu-Qiong Huang3 Departments of 1Obstetrics and Gynecology, 2Ultrasound, 3Laboratory Medicine, Fuzhou Municipal First Hospital Affiliated to Fujian Medical University, Fuzhou 350009, Fujian Province, The People’s Republic of China Received November 1, 2019; Accepted January 26, 2020; Epub February 1, 2020; Published February 15, 2020 Abstract: Background: Kabuki syndrome is a rare multiple congenital anomaly syndrome characterized by distinct facial features, intellectual disability, cardiovascular and musculoskeletal abnormalities, persistence of fetal finger- tip pads, and postnatal growth deficiency. Currently, the diagnosis mainly depends on clinical manifestations and genetic testing. To date, there is no report on the identification Kabuki syndrome in fetuses using chromosomal microarray analysis (CMA). Case presentation: A fetus was identified with growth retardation and cardiovascular abnormality on color Doppler ultrasonography; however, non-invasive prenatal testing (NIPT) revealed a low risk and G-banding karyotyping revealed no abnormal karyotype detected. CMA identified a 1.3 Mb deletion on the X chromosome (Xp11.3) containing KDM6A, DUSP21, MIR222, MIR221 and CXorf36 genes. The fetus was diagnosed with Kabuki syndrome 2, and labor was induced. In addition, CMA detected a 1.3 Mb deletion in the chromosome Xp11.3 in the mother, which contains 5 genes namely KDM6A, DUSP21, MIR222, MIR221 and CXorf36, while no chromosomal abnormality was identified in the father. Conclusions: We report a fetus with Kabuki syndrome 2 detected using CMA.
    [Show full text]
  • Cytoplasmic Activation-Induced Cytidine Deaminase (AID) Exists in Stoichiometric Complex with Translation Elongation Factor 1Α (Eef1a)
    Cytoplasmic activation-induced cytidine deaminase (AID) exists in stoichiometric complex with translation elongation factor 1α (eEF1A) Julien Häsler, Cristina Rada, and Michael S. Neuberger1 Medical Research Council Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom Edited by Frederick W. Alt, Howard Hughes Medical Institute, Harvard Medical School, Children’s Hospital Immune Disease Institute, Boston, MA, and approved October 12, 2011 (received for review April 27, 2011) Activation-induced cytidine deaminase (AID) is a B lymphocyte- results reveal that endogenous cytoplasmic AID partakes in a specific DNA deaminase that acts on the Ig loci to trigger antibody complex containing stoichiometric quantities of translation elon- gene diversification. Most AID, however, is retained in the cyto- gation factor 1α (eEF1A), with this association likely implicated in plasm and its nuclear abundance is carefully regulated because the regulation of AID’s intracellular trafficking. off-target action of AID leads to cancer. The nature of the cytosolic AID complex and the mechanisms regulating its release from the Results cytoplasm and import into the nucleus remain unknown. Here, we Flag-Tagging the Endogenous AID Locus in DT40 Cells. We generated show that cytosolic AID in DT40 B cells is part of an 11S complex derivatives of the DT40 B-cell line in which the endogenous AID and, using an endogenously tagged AID protein to avoid overex- locus was modified so as to incorporate a single Flag tag at the pression artifacts, that it is bound in good stoichiometry to the AID N terminus. To allow targeting of both alleles, one targeting translation elongation factor 1 alpha (eEF1A).
    [Show full text]
  • To Study Mutant P53 Gain of Function, Various Tumor-Derived P53 Mutants
    Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science By Shama K Khokhar M.Sc., Bilaspur University, 2004 B.Sc., Bhopal University, 2002 2007 1 COPYRIGHT SHAMA K KHOKHAR 2007 2 WRIGHT STATE UNIVERSITY SCHOOL OF GRADUATE STUDIES Date of Defense: 12-03-07 I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION BY SHAMA KHAN KHOKHAR ENTITLED Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science Madhavi P. Kadakia, Ph.D. Thesis Director Daniel Organisciak , Ph.D. Department Chair Committee on Final Examination Madhavi P. Kadakia, Ph.D. Steven J. Berberich, Ph.D. Michael Leffak, Ph.D. Joseph F. Thomas, Jr., Ph.D. Dean, School of Graduate Studies 3 Abstract Khokhar, Shama K. M.S., Department of Biochemistry and Molecular Biology, Wright State University, 2007 Differential effect of TAp63γ mutants on transactivation of p53 and/or p63 responsive genes and their effects on global gene expression. p63, a member of the p53 gene family, known to play a role in development, has more recently also been implicated in cancer progression. Mice lacking p63 exhibit severe developmental defects such as limb truncations, abnormal skin, and absence of hair follicles, teeth, and mammary glands. Germline missense mutations of p63 have been shown to be responsible for several human developmental syndromes including SHFM, EEC and ADULT syndromes and are associated with anomalies in the development of organs of epithelial origin.
    [Show full text]
  • Transcriptional Repression of IFN Regulatory Factor 7 by MYC Is Critical for Type I IFN Production in Human Plasmacytoid Dendrit
    Transcriptional Repression of IFN Regulatory Factor 7 by MYC Is Critical for Type I IFN Production in Human Plasmacytoid Dendritic Cells This information is current as of September 28, 2021. Tae Whan Kim, Seunghee Hong, Yin Lin, Elise Murat, HyeMee Joo, Taeil Kim, Virginia Pascual and Yong-Jun Liu J Immunol 2016; 197:3348-3359; Prepublished online 14 September 2016; doi: 10.4049/jimmunol.1502385 Downloaded from http://www.jimmunol.org/content/197/8/3348 Supplementary http://www.jimmunol.org/content/suppl/2016/09/14/jimmunol.150238 http://www.jimmunol.org/ Material 5.DCSupplemental References This article cites 74 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/197/8/3348.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 28, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Transcriptional Repression of IFN Regulatory Factor 7 by MYC Is Critical for Type I IFN Production in Human Plasmacytoid Dendritic Cells Tae Whan Kim,*,1 Seunghee Hong,*,1 Yin Lin,* Elise Murat,* HyeMee Joo,* Taeil Kim,†,2 Virginia Pascual,* and Yong-Jun Liu*,† Type I IFNs are crucial mediators of human innate and adaptive immunity and are massively produced from plasmacytoid dendritic cells (pDCs).
    [Show full text]
  • Longitudinal Peripheral Blood Transcriptional Analysis of COVID-19 Patients
    medRxiv preprint doi: https://doi.org/10.1101/2020.05.05.20091355; this version posted May 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 1 Longitudinal peripheral blood transcriptional analysis of COVID-19 patients 2 captures disease progression and reveals potential biomarkers 3 Qihong Yan1,5,†, Pingchao Li1,†, Xianmiao Ye1,†, Xiaohan Huang1,5,†, Xiaoneng Mo2, 4 Qian Wang1, Yudi Zhang1, Kun Luo1, Zhaoming Chen1, Jia Luo1, Xuefeng Niu3, Ying 5 Feng3, Tianxing Ji3, Bo Feng3, Jinlin Wang2, Feng Li2, Fuchun Zhang2, Fang Li2, 6 Jianhua Wang1, Liqiang Feng1, Zhilong Chen4,*, Chunliang Lei2,*, Linbing Qu1,*, Ling 7 Chen1,2,3,4,* 8 1Guangzhou Regenerative Medicine and Health-Guangdong Laboratory 9 (GRMH-GDL), Guangdong Laboratory of Computational Biomedicine, Guangzhou 10 Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 11 China 12 2Guangzhou Institute of Infectious Disease, Guangzhou Eighth People’s Hospital, 13 Guangzhou Medical University, Guangzhou, China 14 3State Key Laboratory of Respiratory Disease, National Clinical Research Center for 15 Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated 16 Hospital of Guangzhou Medical University, Guangzhou, China 17 4School of Medicine, Huaqiao University, Xiamen, China 18 5University of Chinese Academy of Science, Beijing, China 19 †These authors contributed equally to this work. 20 *To whom correspondence should be addressed: Ling Chen ([email protected]), 21 Linbing Qu ([email protected]), Chunliang Lei ([email protected]), Zhilong 22 Chen ([email protected]) NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Functional Genomics Atlas of Synovial Fibroblasts Defining Rheumatoid Arthritis
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.16.20248230; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Functional genomics atlas of synovial fibroblasts defining rheumatoid arthritis heritability Xiangyu Ge1*, Mojca Frank-Bertoncelj2*, Kerstin Klein2, Amanda Mcgovern1, Tadeja Kuret2,3, Miranda Houtman2, Blaž Burja2,3, Raphael Micheroli2, Miriam Marks4, Andrew Filer5,6, Christopher D. Buckley5,6,7, Gisela Orozco1, Oliver Distler2, Andrew P Morris1, Paul Martin1, Stephen Eyre1* & Caroline Ospelt2*,# 1Versus Arthritis Centre for Genetics and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK 2Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland 3Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia 4Schulthess Klinik, Zurich, Switzerland 5Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK 6NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham, UK 7Kennedy Institute of Rheumatology, University of Oxford Roosevelt Drive Headington Oxford UK *These authors contributed equally #corresponding author: [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2020.12.16.20248230; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • The Role of Microrna in Human Leukemia: a Review
    Leukemia (2009) 23, 1257–1263 & 2009 Macmillan Publishers Limited All rights reserved 0887-6924/09 $32.00 www.nature.com/leu SPOTLIGHT REVIEW The role of microRNA in human leukemia: a review S Yendamuri1 and GA Calin2 1Department of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, NY, USA and 2Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA MicroRNAs (miRNAs or miRs) are 18–22-nucleotide non-coding target. If the sequence is a perfect match, the final result seems RNAs that have emerged as a new paradigm of epigenetic to be target mRNA degradation in a manner similar to siRNA- regulation in both normal development and cellular function, and in the pathogenesis of human disease including cancer. induced gene expression silencing. This seems to be the This review summarizes the current literature of mechanism of predominant mechanism in plants. A less than perfect match gene regulation by miRNA and their role in hematopoiesis and may result in inefficient translation leading to effective down- leukemogenesis. An understanding of these processes sug- regulation of the gene, a mechanism more common in gests further avenues for research to understand gene regula- animals.7–9 Isolated examples of miRNA leading to upregulation tion and miRNA-based therapeutic approaches. of genes have been reported.10 Leukemia (2009) 23, 1257–1263; doi:10.1038/leu.2008.382; The mechanism of translational repression is known only published online 15 January 2009 11 Keywords: microRNA; non-coding RNA; microarray; partially. The mRNA segments that miRNAs bind seem to be mostly in the 30UTRs of genes.
    [Show full text]
  • Development and Validation of a Novel Immune-Related Prognostic Model
    Wang et al. J Transl Med (2020) 18:67 https://doi.org/10.1186/s12967-020-02255-6 Journal of Translational Medicine RESEARCH Open Access Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma Zheng Wang1, Jie Zhu1, Yongjuan Liu3, Changhong Liu2, Wenqi Wang2, Fengzhe Chen1* and Lixian Ma1* Abstract Background: Growing evidence has suggested that immune-related genes play crucial roles in the development and progression of hepatocellular carcinoma (HCC). Nevertheless, the utility of immune-related genes for evaluating the prognosis of HCC patients are still lacking. The study aimed to explore gene signatures and prognostic values of immune-related genes in HCC. Methods: We comprehensively integrated gene expression data acquired from 374 HCC and 50 normal tissues in The Cancer Genome Atlas (TCGA). Diferentially expressed genes (DEGs) analysis and univariate Cox regression analysis were performed to identify DEGs that related to overall survival. An immune prognostic model was constructed using the Lasso and multivariate Cox regression analyses. Furthermore, Cox regression analysis was applied to identify independent prognostic factors in HCC. The correlation analysis between immune-related signature and immune cells infltration were also investigated. Finally, the signature was validated in an external independent dataset. Results: A total of 329 diferentially expressed immune‐related genes were detected. 64 immune‐related genes were identifed to be markedly related to overall survival in HCC patients using univariate Cox regression analysis. Then we established a TF-mediated network for exploring the regulatory mechanisms of these genes. Lasso and multivariate Cox regression analyses were applied to construct the immune-based prognostic model, which consisted of nine immune‐related genes.
    [Show full text]
  • Supp Material.Pdf
    Simon et al. Supplementary information: Table of contents p.1 Supplementary material and methods p.2-4 • PoIy(I)-poly(C) Treatment • Flow Cytometry and Immunohistochemistry • Western Blotting • Quantitative RT-PCR • Fluorescence In Situ Hybridization • RNA-Seq • Exome capture • Sequencing Supplementary Figures and Tables Suppl. items Description pages Figure 1 Inactivation of Ezh2 affects normal thymocyte development 5 Figure 2 Ezh2 mouse leukemias express cell surface T cell receptor 6 Figure 3 Expression of EZH2 and Hox genes in T-ALL 7 Figure 4 Additional mutation et deletion of chromatin modifiers in T-ALL 8 Figure 5 PRC2 expression and activity in human lymphoproliferative disease 9 Figure 6 PRC2 regulatory network (String analysis) 10 Table 1 Primers and probes for detection of PRC2 genes 11 Table 2 Patient and T-ALL characteristics 12 Table 3 Statistics of RNA and DNA sequencing 13 Table 4 Mutations found in human T-ALLs (see Fig. 3D and Suppl. Fig. 4) 14 Table 5 SNP populations in analyzed human T-ALL samples 15 Table 6 List of altered genes in T-ALL for DAVID analysis 20 Table 7 List of David functional clusters 31 Table 8 List of acquired SNP tested in normal non leukemic DNA 32 1 Simon et al. Supplementary Material and Methods PoIy(I)-poly(C) Treatment. pIpC (GE Healthcare Lifesciences) was dissolved in endotoxin-free D-PBS (Gibco) at a concentration of 2 mg/ml. Mice received four consecutive injections of 150 μg pIpC every other day. The day of the last pIpC injection was designated as day 0 of experiment.
    [Show full text]
  • TITLE PAGE Oxidative Stress and Response to Thymidylate Synthase
    Downloaded from molpharm.aspetjournals.org at ASPET Journals on October 2, 2021 -Targeted -Targeted 1 , University of of , University SC K.W.B., South Columbia, (U.O., Carolina, This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted.
    [Show full text]
  • Transcriptomic and Proteomic Profiling Provides Insight Into
    BASIC RESEARCH www.jasn.org Transcriptomic and Proteomic Profiling Provides Insight into Mesangial Cell Function in IgA Nephropathy † † ‡ Peidi Liu,* Emelie Lassén,* Viji Nair, Celine C. Berthier, Miyuki Suguro, Carina Sihlbom,§ † | † Matthias Kretzler, Christer Betsholtz, ¶ Börje Haraldsson,* Wenjun Ju, Kerstin Ebefors,* and Jenny Nyström* *Department of Physiology, Institute of Neuroscience and Physiology, §Proteomics Core Facility at University of Gothenburg, University of Gothenburg, Gothenburg, Sweden; †Division of Nephrology, Department of Internal Medicine and Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan; ‡Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan; |Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; and ¶Integrated Cardio Metabolic Centre, Karolinska Institutet Novum, Huddinge, Sweden ABSTRACT IgA nephropathy (IgAN), the most common GN worldwide, is characterized by circulating galactose-deficient IgA (gd-IgA) that forms immune complexes. The immune complexes are deposited in the glomerular mesangium, leading to inflammation and loss of renal function, but the complete pathophysiology of the disease is not understood. Using an integrated global transcriptomic and proteomic profiling approach, we investigated the role of the mesangium in the onset and progression of IgAN. Global gene expression was investigated by microarray analysis of the glomerular compartment of renal biopsy specimens from patients with IgAN (n=19) and controls (n=22). Using curated glomerular cell type–specific genes from the published literature, we found differential expression of a much higher percentage of mesangial cell–positive standard genes than podocyte-positive standard genes in IgAN. Principal coordinate analysis of expression data revealed clear separation of patient and control samples on the basis of mesangial but not podocyte cell–positive standard genes.
    [Show full text]
  • A Curated Database of Experimentally Identified Interaction Proteins Of
    International Journal of Molecular Sciences Article OGT Protein Interaction Network (OGT-PIN): A Curated Database of Experimentally Identified Interaction Proteins of OGT Junfeng Ma 1,* , Chunyan Hou 2, Yaoxiang Li 1 , Shufu Chen 3 and Ci Wu 1 1 Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, USA; [email protected] (Y.L.); [email protected] (C.W.) 2 Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; [email protected] 3 School of Engineering, Pennsylvania State University Behrend, Erie, PA 16563, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-202-6873802 Abstract: Interactions between proteins are essential to any cellular process and constitute the basis for molecular networks that determine the functional state of a cell. With the technical advances in recent years, an astonishingly high number of protein–protein interactions has been revealed. However, the interactome of O-linked N-acetylglucosamine transferase (OGT), the sole enzyme adding the O-linked β-N-acetylglucosamine (O-GlcNAc) onto its target proteins, has been largely undefined. To that end, we collated OGT interaction proteins experimentally identified in the past several decades. Rigorous curation of datasets from public repositories and O-GlcNAc-focused publications led to the identification of up to 929 high-stringency OGT interactors from multiple species studied (including Homo sapiens, Mus musculus, Rattus norvegicus, Drosophila melanogaster, Citation: Ma, J.; Hou, C.; Li, Y.; Chen, S.; Wu, C. OGT Protein Interaction Arabidopsis thaliana, and others). Among them, 784 human proteins were found to be interactors Network (OGT-PIN): A Curated of human OGT.
    [Show full text]